Sprague-Dawley (SD) Rat Mesenchymal Stem Cells with RFP

  • Specification
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C1315
Description
SD Rat bone marrow mesenchymal stem cells are extracted from healthy SD Rats bone marrow and have strong proliferation and multi-directional differentiation capabilities. After adherent culture, use lentiviral transduction with RFP gene to make the cells stably express RFP. It can be used as a cell model to study proliferation, aging, immunity, differentiation and transplantation.
Species
Rat
Recommended Medium
Rat Bone Marrow Mesenchymal Stem Cells Complete Medium
Application
For Research Use Only
Shipping
Dry Ice
Quality Control
Sterility, Safety, HIV/viruses, bacteria, fungi: negative.
Storage and Shipping
Remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Abstract No. 314 Pre-operative Portal Vein Ligation and MSC Injection in a Rat Model

Journal of Vascular and Interventional Radiology | DOI | Paper |

Background

Preoperative portal vein ligation (PVL) redirects portal flow to the future liver remnant (FLR) to induce hypertrophy before hepatic resection. This study investigated whether mesenchymal stem cells (MSCs) can augment PVL in a rat model. RFP-labeled Sprague-Dawley rat bone-marrow-derived MSCs were injected into non-occluded portal branches after PVL. CT volumetry, necropsy, and histology assessed FLR growth and MSC presence. MSC addition improved liver hypertrophy, suggesting a potential adjunct strategy for liver cancer resection.

Key Findings

All rats survived for two weeks with no complications. CT volumetry showed that PVL+MSC rats had a 70.2% increase in non-ligated liver volume (1.54 to 3.08 mL), compared with a 41.4% increase in PVL-only rats (1.19 to 1.91 mL) and a decrease in controls (2.99 to 1.35 mL). Necropsy revealed the highest future liver remnant (FLR)-to-total weight ratio in the PVL+MSC group. Histological evaluation confirmed RFP-labeled MSCs only in the PVL+MSC group, not in PVL or control groups. These results indicate that MSC injection can enhance PVL-induced liver hypertrophy in this rat model, supporting further research into MSC retention and clinical translation for liver resection.

Contribution

Creative Bioarray provided the RFP-labeled Sprague-Dawley rat bone-marrow-derived mesenchymal stem cells (MSCs) used in the PVL+MSC group. This material enabled histologic tracking and assessment of MSC-enhanced liver hypertrophy after preoperative portal vein ligation in the rat model, supporting the study's key findings.

Fig. 1.

Injectable, electrosprayed RGD-coupled alginate hydrogel microcapsules enable enhanced viability and sustained release of mesenchymal stem cells

Biomedical Microdevices | DOI | Paper |

Background

This study develops an injectable cell-delivery platform using electrosprayed RGD-coupled alginate (RAlg) microcapsules to enhance mesenchymal stem cell (MSC) viability and sustained release. Electrospray parameters were optimized to produce uniform microcapsules (~175 µm) with a microporous architecture. RGD conjugation did not significantly alter swelling, viscoelasticity, or encapsulation efficiency. Encapsulated MSCs remained viable, with RAlg maintaining 91.3% viability after 14 days versus 84.9% for alginate alone. Both formulations showed comparable time-dependent cell release, supporting RAlg microcapsules as a biocompatible, injectable platform for regenerative medicine.

Key Findings

Electrospraying parameters were optimized (7 kV, 0.1 mL/min, 80 µm needle, 2% alginate) to fabricate uniform microcapsules with a mean diameter of 175.4 ± 21.1 µm. Electron microscopy revealed a rough surface and an ordered microporous architecture with pores <200 nm. RGD conjugation did not significantly alter swelling, viscoelasticity at low concentrations, or encapsulation efficiency; both alginate and RAlg achieved >92% encapsulation. MSCs were successfully encapsulated and exhibited a round morphology. Over 14 days, RAlg microcapsules maintained significantly higher MSC viability (91.3%) than unmodified alginate (84.9%), with differences emerging by day 3. Both microcapsule types showed comparable time-dependent release: mostly intact at day 1, 59–61% cell release by day 7, and 78–81% release by day 14. These results indicate that electrosprayed RAlg microcapsules provide enhanced viability and sustained release, offering a biocompatible injectable delivery platform for MSC therapies.

Contribution

Creative Bioarray provided the bone marrow-derived Sprague-Dawley red fluorescent protein (RFP)-mesenchymal stem cells (MSCs) used throughout the study. These cells enabled visualization of encapsulation, viability assessment, and release experiments, supporting the evaluation of electrosprayed RAlg microcapsules as an injectable MSC delivery platform.

Scanning electron microscopy (SEM) imaging and MSC viability assessment of MSC-loaded alginate (MSC-Alg) and RGD-coupled (MSC-RAlg) microcapsules.
Fig. 2. Scanning electron microscopy (SEM) imaging and MSC viability assessment of MSC-loaded alginate (MSC-Alg) and RGD-coupled (MSC-RAlg) microcapsules.

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products